(Reuters) - Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an about 3 percent fall in quarterly profit, missing estimates, hurt by headwinds in the U.S. market.
Profit for the quarter ended March 31 came in at 3.02 billion rupees ($44.40 million) versus 3.13 billion rupees a year earlier, the company said https://www.bseindia.com/xml-data/corpfiling/AttachLive/280bdd33-dda4-4c5f-8624-b01b7efaeb68.pdf.
Analysts on average estimated a profit of 3.59 billion rupees, according to Thomson Reuters data.
Revenue fell slightly to 35.35 billion rupees.
Also Read
($1 = 68.0175 Indian rupees)
(Reporting By Arnab Paul in Bengaluru; Editing by Biju Dwarakanath)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app